Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaniprevir + pegylated interferon + ribavirin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapy consists of **vaniprevir** (MK-7009), a macrocyclic small molecule inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease, combined with **pegylated interferon alpha-2a or alpha-2b** (PegIFN), and **ribavirin**, a nucleoside analog antiviral. Vaniprevir acts as a non-covalent competitive inhibitor of the HCV NS3/4A protease, blocking viral replication. Pegylated interferon works by stimulating host antiviral immune responses, while ribavirin interferes with viral RNA synthesis. This triple regimen has been studied for the treatment of chronic hepatitis C infection, primarily genotype 1, in both treatment-naïve and previously treated patients. The combination results in a greater and more rapid reduction in plasma HCV RNA levels compared to pegylated interferon plus ribavirin alone. [1][4][3][5]
- Other names
- vaniprevir + pegylated interferon + ribavirin
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on vaniprevir + pegylated interferon + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaniprevir + pegylated interferon + ribavirin.